Mechlorethamine Pregnancy and Breastfeeding Warnings

Brand names: Mustargen

Mechlorethamine Pregnancy Warnings

Use during pregnancy should be avoided.

US FDA pregnancy category: D

Comments: If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential harm to the fetus. Women of childbearing potential should be advised to avoid pregnancy.

Animal studies have revealed evidence of fetal malformations. There are no adequate and well-controlled studies in pregnant women. Treatment may be followed by delayed catamenia, oligomenorrhea, or amenorrhea. Impaired spermatogenesis, azoospermia and total germinal aplasia have been reported in male patients treated with alkylating agents, especially in combination with other drugs. Patients should be warned of the potential risk to their reproductive capacity.

US FDA pregnancy category D: There is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience or studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.

See references

Mechlorethamine Breastfeeding Warnings

A decision should be made whether to discontinue breastfeeding or to discontinue the drug, taking into account the importance of the drug to the mother.

Excreted into human milk: Unknown
Excreted into animal milk: Data not available

Comments: The effects in the nursing infant are unknown.

See references

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer